Mammalian Cell Fermentation Technology Market (2026 - 2033)

Mammalian Cell Fermentation Technology Market Summary

The global mammalian cell fermentation technology market size was valued at USD 50.4 billion in 2025 and is projected to grow from USD 54.7 billion in 2026 to USD 97.8 billion in 2033, at a CAGR of 8.6% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 37.0% in 2025. Mammalian cells are commonly used to manufacture therapeutic proteins such as monoclonal antibodies, vaccines, and other biologics, along with several cell lines, including Chinese Hamster Ovary (CHO) cells, Human Embryonic Kidney (HEK) cells, and others. The increasing prevalence of chronic diseases, coupled with the growing demand for biologics, is fueling the demand for fermentation technologies.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

The market for mammalian cell fermentation technology is experiencing a significant surge due to the rising demand for biologics and biosimilars. These treatments have become crucial in managing various ailments, including cancer, autoimmune conditions, and infectious diseases. As pharmaceutical companies increasingly invest in developing new biologics, interest in mammalian cell fermentation technology continues to grow. For instance, in June 2025, WuXi Biologics announced plans to construct a new commercial biomanufacturing facility in Chengdu, China. The site will feature advanced biologics production capabilities, including a 15,000 L fermentation system with the potential for future expansion to 60,000 L, supporting the growing global demand for biologics and recombinant therapeutics. This investment highlights the increasing adoption of advanced cell culture and fermentation technologies to expand biologics manufacturing capacity worldwide.

Technological developments in cell culture are another driver boosting the market for mammalian cell fermentation. Higher yields of recombinant proteins and other biologics can now be achieved with serum-free media and advances in bioreactor technologies, which have fundamentally transformed the industry.

The market for mammalian cell fermentation technology has expanded due to the rise in chronic diseases such as diabetes, heart disease, and cancer. There is a constant need for mammalian cell fermentation tools because many illnesses necessitate long-term therapy, frequently with biologics. Overall, it is anticipated that the market for mammalian cell fermentation technology will expand over the next several years due to the ongoing need for biologics and biosimilars and advances in the treatment of chronic diseases.

Analyst Perspective

The mammalian cell fermentation technology market is expected to witness robust growth, driven by the rising demand for complex biologics, including monoclonal antibodies, recombinant proteins, vaccines, biosimilars, and cell & gene therapies, used in the treatment of chronic diseases such as cancer, diabetes, and autoimmune disorders. Mammalian cell-based fermentation plays a critical role in biopharmaceutical manufacturing due to its ability to produce complex proteins with high biological activity and human-like post-translational modifications. Continuous advancements in cell culture media, bioreactor technologies, cell line engineering, single-use systems, and process automation are improving production efficiency, product quality, and scalability. In addition, expanding investments in biomanufacturing infrastructure, capacity expansion initiatives, and rising dependence on CDMO services are accelerating market growth. The expanding biologics pipeline, increasing regulatory approvals for biologics and biosimilars, and ongoing innovation in bioprocessing technologies are expected to create significant growth opportunities for market participants throughout the forecast period.

Type Insights

The Chinese Hamster Ovary (CHO) cell fermentation segment dominated the mammalian cell fermentation technology market in 2025, accounting for approximately 65.0% of the market. This dominance is attributed to its ability to produce high yields of complex recombinant proteins with human-like post-translational modifications, along with its well-established genetic and biochemical characteristics. CHO cells have become the preferred mammalian expression system in the biopharmaceutical industry due to their proven safety profile, scalability, regulatory acceptance, and decades of process optimization. These advantages make them highly suitable for the large-scale production of monoclonal antibodies, recombinant proteins, and other biologics. For instance, in May 2025, Samsung Biologics expanded its antibody-drug conjugate (ADC) manufacturing capabilities and continued to strengthen its large-scale CHO cell-based biologics production platform to support growing global demand for biologics and biosimilars. This development highlights the continued reliance of leading biopharmaceutical manufacturers on CHO cell fermentation technology for commercial biologics production, thereby supporting growth in the mammalian cell fermentation technology market.

Human Embryonic Kidney (HEK) cell fermentation is used in biotechnology and pharmaceutical research because HEK cells proliferate rapidly and produce large amounts of recombinant proteins. The segment is expected to grow at the fastest CAGR by 2033. The simplicity of HEK cell growth and culture maintenance further makes them a desirable option for large-scale fermentation. Due to its high productivity, scalability, and affordability, the HEK cells fermentation technology market is rapidly expanding, making it the fastest-growing sector in the mammalian cells fermentation technology market. As a result, the HEK cell fermentation segment is expected to continue growing rapidly.

Application Insights

The monoclonal antibodies segment held a dominant share of approximately 42.0% in 2025, driven by their critical role in biologics development and their high specificity and effectiveness in treating a wide range of diseases, including cancer, autoimmune disorders, and infectious diseases. The segment is further supported by the rising prevalence of chronic diseases, increasing regulatory approvals for biologics, growing adoption of targeted therapies, and expanding investments in antibody-based drug development. Mammalian cell fermentation enables scalable, high-yield production of these complex antibody therapies, with strong regulatory acceptance and consistent product quality. In addition, advancements in cell line engineering, bioprocess optimization, and large-scale biomanufacturing technologies are improving production efficiency, enhancing product consistency, and accelerating commercialization. The continued expansion of biologics pipelines, rising demand for personalized therapies, and increasing focus on innovative antibody-based treatments are expected to further drive growth in the monoclonal antibodies segment of the mammalian cell fermentation technology market.

The recombinant protein segment is expected to grow at a significant CAGR during the forecast period, as these proteins are widely used in pharmaceuticals, vaccines, and diagnostic applications. Produced through genetic engineering in mammalian expression systems, recombinant proteins offer high structural accuracy and biological functionality, making them essential in modern therapeutic development. The segment growth is further driven by increasing demand for targeted biologics, rising investments in biopharmaceutical R&D, and expanding applications of recombinant proteins in therapeutic and diagnostic development. Continuous improvements in gene expression systems, cell line engineering, and upstream processing are further accelerating production efficiency and scalability, supporting the strong growth of this segment.

End use Insights

The CMOs & CDMOs segment dominated the market, accounting for approximately 51.00% of the market in 2025. The dominance is due to their ability to offer comprehensive services to pharmaceutical and biotech companies, including process development and large-scale manufacturing, and to provide flexible business models to their clients. The segment is further driven by increasing outsourcing of biologics manufacturing to reduce operational costs, accelerate time-to-market, and improve production scalability. In addition, rising investments in biologics development, expanding biosimilar pipelines, and growing demand for specialized manufacturing capabilities are further supporting segment growth. For instance, in April 2025, FUJIFILM Diosynth Biotechnologies signed a 10-year manufacturing agreement valued at over USD 3 billion with Regeneron Pharmaceuticals Inc. to support large-scale biologics production at its U.S. manufacturing facility.

The biopharmaceutical companies segment is expected to grow at a significant CAGR during the forecast period, driven by the rising demand for biologics, advanced therapies, and personalized medicine. The increasing prevalence of chronic diseases, expanding biologics pipelines, and growing adoption of targeted therapies are key factors supporting segment growth. Mammalian cell fermentation technology plays a critical role in biopharmaceutical manufacturing by enabling the production of complex biologics with high efficacy, safety, and consistency. Advancements in cell line engineering, bioprocess optimization, and large-scale manufacturing technologies have further improved production efficiency, scalability, and cost-effectiveness. In addition, increasing investments in biopharmaceutical R&D, expanding manufacturing capacity, and a growing focus on innovative therapeutic development are expected to further drive growth in the biopharmaceutical companies segment of the mammalian cell fermentation technology market.

Regional Insights

North America dominated the market, accounting for a revenue share of 37.0% of the market. The region has a highly developed healthcare infrastructure, favorable government policies, and a strong presence of major biopharmaceutical companies, all of which drive market growth. In addition, the increasing prevalence of chronic diseases and rising demand for biologics and biosimilars have also contributed to the growth of the market in the region. For instance, in April 2025, Amgen Inc. announced a USD 900 million expansion of its Ohio manufacturing facility, increasing its investment in the state to more than USD 1.4 billion. The expansion is expected to strengthen the company's biologics manufacturing capabilities and support growing global demand for innovative biopharmaceutical products, thereby contributing to the growth of the mammalian cell fermentation technology market in North America.

To learn more about this report, Download Free Sample Report

Asia Pacific Mammalian Cell Fermentation Technology Market Trends

The Asia Pacific region is estimated to grow at the fastest rate during the forecast period. This can be attributed to the expansion of the mammalian cell fermentation technology industry in the region, driven by a favorable regulatory environment, rising investments by multinational corporations, and the availability of trained staff at reduced cost. For instance, in December 2025, Thermo Fisher Scientific expanded its bioprocessing footprint across Asia by launching a new Bioprocess Design Center in Hyderabad, India, and expanding existing centers in Incheon, South Korea, and Singapore. The investment aims to support the region's rapidly growing biopharmaceutical industry and accelerate biologics manufacturing capabilities. The market for mammalian cell fermentation technology in the Asia Pacific region is expected to grow in the coming years due to these investments.

Key Mammalian Cell Fermentation Technology Market Company Insights

The growing demand for mammalian cell fermentation technology for various applications has created numerous market opportunities for key players to capitalize on. Several players are involved in initiatives such as acquisitions, mergers, and collaborations to strengthen their market position. For instance, in June 2025, AstraZeneca entered into a strategic collaboration with CSPC Pharmaceuticals to advance the discovery and development of novel therapeutics across multiple chronic disease indications. The agreement leverages CSPC's AI-driven drug discovery platform and highlights the increasing emphasis on strategic partnerships to expand biologics pipelines and accelerate the development of next-generation therapies.

Key Mammalian Cell Fermentation Technology Companies

The following key companies have been profiled for this study on the mammalian cell fermentation technology market:

• Thermo Fisher Scientific, Inc.

• Merck KGaA

• Danaher Corporation

• Lonza

• F. Hoffmann-La Roche Ltd

• Sartorius AG

• AstraZeneca

• Bristol-Myers Squibb Company

• Amgen Inc.

• Gilead Sciences, Inc.

• Moderna, Inc.

• Regeneron Pharmaceuticals Inc.

Recent Developments

• In April 2025, Thermo Fisher Scientific announced an additional USD 2 billion investment in the U.S. over the next four years to strengthen manufacturing capacity and innovation across the life sciences sector. The investment includes USD 1.5 billion to expand and enhance U.S. manufacturing operations and USD 500 million for R&D focused on high-impact innovation.

• In October 2025, Merck KGaA signed a definitive agreement to acquire JSR Life Sciences’ chromatography business to strengthen its downstream bioprocessing portfolio, particularly in Protein A chromatography used for monoclonal antibody purification. This development enhances Merck’s integrated biologics manufacturing capabilities and supports scalable mammalian cell culture-based production.

Global Mammalian Cell Fermentation Technology Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global mammalian cell fermentation technology market report based on type, application, end use, and region:

• Type Outlook (Revenue, USD Billion, 2021 - 2033)

  • Chinese Hamster Ovary (CHO) Cell Fermentation

  • Human Embryonic Kidney (HEK) Cell Fermentation

  • Baby Hamster Kidney (BHK) Cell Fermentation

  • Murine Myeloma Cell Fermentation

  • Others

• Application Outlook (Revenue, USD Billion, 2021 - 2033)

  • Monoclonal Antibodies

  • Recombinant Proteins

  • Vaccines

  • Hormones

  • Enzymes

  • Others

• End Use Outlook (Revenue, USD Billion, 2021 - 2033)

  • Biopharmaceutical Companies

  • CMOs & CDMOs

  • Academic & Research Institutes

• Regional Outlook (Revenue, USD Billion, 2021 - 2033)

  • North America

    • U.S.

    • Canada

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait